Phase II Study of Allo LMI Vaccine With IL-2 for Stable Metastatic Breast Ca

Breast Cancer Clinical Trial

Official title:

A Phase II Study of Allogeneic Large Multivalent Immunogen (LMI) Vaccine and IL-2 for the Treatment of Stable Metastatic Breast Cancer

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00784524
• Other study ID #: 2007LS094
• Secondary ID: 0802M25946
• Status: Terminated
• Phase: Phase 2
• Start date: September 2008
• Est. completion date: July 2014

Study information

• Verified date: May 2019
• Source: Masonic Cancer Center, University of Minnesota
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

RATIONALE: Vaccines may help the body build an effective immune response to kill tumor cells. Aldesleukin may stimulate the white blood cells to kill breast cancer cells. Giving vaccine therapy together with aldesleukin may be a more effective treatment for metastatic breast cancer.

PURPOSE: This phase II trial is studying how well giving vaccine therapy together with aldesleukin works in treating women with metastatic breast cancer.

Description:

OBJECTIVES:

Primary

• To determine the efficacy of allogeneic large multivalent immunogen (LMI) vaccine and aldesleukin, as defined by clinical benefit rate (percentage of patients demonstrating a complete response, partial response, or disease stabilization as assessed by RECIST criteria), in women with stable metastatic breast cancer.

Secondary

• To measure the immune response in patients treated with this regimen.

• To determine the progression-free survival of patients treated with this regimen.

• To determine the 1- and 2-year overall survival rates in patients treated with this regimen.

• To determine the safety profile and toxicity of this regimen in these patients.

OUTLINE: Patients receive allogeneic large multivalent immunogen (LMI) vaccine intradermally on day 1 and aldesleukin subcutaneously on days 7 and 8. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity. Patients with disease progression after 2 courses of vaccine therapy resume the chemotherapy regimen for which prior disease stabilization was achieved. Beginning 2-4 days after completion of chemotherapy, patients receive one dose of LMI vaccine followed by aldesleukin on days 7 and

8. Patients achieving at least stable disease continue to receive LMI vaccine and aldesleukin as above. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.

Peripheral blood mononuclear cell samples are collected periodically for research studies. Samples are analyzed to assess the frequency of leukocyte subsets (including B cells, T cells, NK cells, and monocytes) via flow cytometry; frequency of T-regs (T cells that express CD4, CD25, and FoxP3); and responses to keyhole limpet hemocyanin and tetanus toxoid via ELISA assay. Other immunological studies are also performed.

After completion of study therapy, patients are followed every 3 months.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 14
• Est. completion date: July 2014
• Est. primary completion date: July 2014
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion criteria:

• Stage IV, metastatic breast cancer, confirmed by histology or cytology.

• Disease must be refractory to hormone therapy for tumors that estrogen and/or progesterone receptor positive

• Disease must be refractory to trastuzumab for tumors that are HER2 positive

• Disease must be responsive to chemotherapy such that regression or at least stabilization occurs

• Stable disease is defined as neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive disease

• Measurement of regressed or stable disease must be confirmed by repeat evaluation no less than 4 weeks after the initial determination.

• Prior systemic chemotherapy, immunotherapy, biological therapy, or investigational drug therapy is allowed if at least 4 weeks since last treatment.

• Patient must recover from the acute toxic effects of the treatment prior to study enrollment.

• There is no limit as to the number of previous chemotherapy regimens received.

• Disease status may be measurable or non-measurable

• Karnofsky performance status >70%

• Women, age 18 years or older

• Adequate organ function within 14 days of study registration including the following:

• Adequate bone marrow reserve: absolute neutrophil (segmented and bands) count (ANC) = 1.5 x 10^9/L, platelets =75 x 10^9/L, and hemoglobin = 8.0 g/dL

• Hepatic: bilirubin = 3 times the upper limit of normal (× ULN) for patients without tumor involvement of the liver and = 5 X ULN for patients with tumor involvement of the liver; aspartate transaminase (AST) = 2.5 × ULN for patients without tumor involvement of the liver and = 5 X ULN for patients with tumor involvement of the liver

• Renal: creatinine = 2.0 mg/dL

• Must share at least one class I HLA allele with the HLA-type SKBR3 cell (class I alleles A2, A3, B14, B40, C3, C8)

• Meets eligibility criteria for and agrees to enroll in "MT1999-06: Vaccination with Tetanus Toxoid and Keyhole Limpet Hemocyanin (KLH) to Assess Antigen-Specific Immune Responses" (IRB # 9904M01581, CPRC #2002LS032). Patients who have had tetanus toxoid within the last 7 years will not receive the tetanus vaccine component. For patients who do not know the year of their last tetanus vaccine, tetanus toxoid will be given per protocol. Subjects allergic to seafood will not be co-enrolled into MT1996-06.

• Women of childbearing potential and their partners are required to use an effective method of contraception (ie, a hormonal contraceptive, intra-uterine device, diaphragm with spermicide, condom with spermicide, or abstinence) during the study and for 3 months after the last dose of study drug.

• Voluntary written informed consent before performance of any study-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudice to future medical care.

Exclusion criteria:

• History of untreated or active brain metastases or positive brain scan at enrollment. Patients with previously treated brain metastases are eligible if stable by CT or MRI for at least 3 months.

• Concurrent malignancy other than non-melanoma skin cancer or carcinoma in situ of the cervix

• Active infection

• Solid organ transplantation or autoimmune diseases requiring systemic immunosuppressive therapy; however, topical or inhalational steroids are allowed.

• Symptomatic pulmonary disease (symptoms of dyspnea or rales, wheezes or rhonchi on physical exam) will require pulmonary function testing (PFTs). Those with FEV1 <50% of predicted or corrected DLCO <50% are not eligible.

• Patients with cardiac disease such as recent myocardial infarction (< 3 months prior), unstable angina, or heart failure requiring medical intervention will undergo cardiac evaluation. Cardiac testing may include ECG, MUGA or echocardiogram, and/or thallium stress test as indicated to evaluate cardiac risks. Those patients with exercise-induced ischemia or an ejection fraction by MUGA or echocardiogram < 40% are not eligible.

• Hypersensitivity to any component of the vaccine, including Thimerosal, a mercury derivative, is a contraindication (taken from tetanus toxoid package insert).

• The occurrence of any type of neurologic symptoms to tetanus vaccine in the past is a contraindication to further use (taken from tetanus toxoid package insert).

• Pregnant (positive pregnancy test) or lactating women. Use of LMI vaccine during pregnancy is not approved for use by the FDA during pregnancy. IL-2 is pregnancy category C - risk in pregnancy cannot be ruled out.

Related Conditions & MeSH terms

• Breast Cancer
• Breast Neoplasms

Intervention

Biological:
• allogeneic large multivalent immunogen breast cancer vaccine
Allogeneic large multivalent immunogen breast cancer vaccine (1 x 10^7, 5-µm silica spheres) will be given as an intradermal injection every 28 days (+/- 3 days). Each vaccine dose will be 0.2 ml.
• aldesleukin
Subcutaneous aldesleukin (10 x 10^6 International Units) will be given on day 7 and day 8 after each LMI injection.

Locations

Country	Name	City	State
United States	Masonic Cancer Center, University of Minnesota	Minneapolis	Minnesota

Sponsors (1)

Lead Sponsor	Collaborator
Masonic Cancer Center, University of Minnesota

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Disease Response	Percentage of patients achieving complete response, partial response, or disease stabilization as assessed by Response Evaluation Criteria In Solid Tumors Criteria (RECIST) criteria for measurable target lesions and non-measurable non-target lesions assessed by CT, PET-CT or MRI: Complete Response (CR), Disappearance of all target and non-target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions or persistence of one or more non-target lesions; Disease Stabilization (SD), Neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive disease; Progressive Disease (PD), >=20% increase in the sum of the longest diameter of target lesions or the appearance of 1 or more new lesions and/or unequivocal progression of existing non-target lesions.	Up to 2 years
Secondary	Immune Response	Immune responses will be assessed by DTH responses to LMI, IFN-gamma production by CD8+ T cells using the ELISPOT assay, and CD8+ T cell binding to HLA-A2 multimers complexed with breast cancer-derived peptides (multimer analysis).	48 hours
Secondary	Progression-free Survival	Progression free survival will be measured in months from time of response to time of disease progression as defined by RECIST (appendix II), "at least a 20% increase in the sum of the longest diameters of target lesions, taking as reference the smallest sum longest diameter recorded since the baseline measurements, or the appearance of one or more new lesion(s)."	Up to 1 year
Secondary	Overall Survival	Number of participants alive at one year	1 Year
Secondary	Overall Survival	Number of participants alive at 2 years	2 years